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Abstract
Background: Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs)
efficaciously reduce systolic blood pressure (BP), a well-established risk factor for myocardial infarction (MI). Both
inhibit the renin-angiotensin system, albeit through different mechanisms, and produce similar reductions in BP.
However, in parallel meta-analyses of ACEi and ARB trials, ACEis reduce risk of MI whereas ARBs do not—a
phenomenon described as the ‘ARB-MI paradox’. In addition, ACEis reduce all-cause mortality, whereas ARBs do not,
which appears to be independent of BP lowering. The divergent cardiovascular effects of ACE inhibitors and ARBs,
despite similar BP reductions, are counter-intuitive. This systematic review aims to ascertain the extent to which
clinical outcomes in randomised trials of ACEi and ARBs are attributable to reductions in systolic BP.
Methods: A comprehensive search of bibliographic databases will be performed to identify all randomised studies of
agents of the ACEi and ARB class. Placebo and active comparator-controlled studies that report clinical outcomes, with
greater than 500 person-years of follow-up in each study arm, will be included. Two independent reviewers will screen
study records against a priori-defined eligibility criteria and perform data extraction. The Cochrane Risk of Bias Tool will
be applied to all included studies. Studies retracted subsequent to initial publication will be excluded. Primary
outcomes of interest include MI and all-cause mortality; secondary outcomes include stroke, heart failure,
revascularisation and cardiovascular mortality. Meta-regression will be performed, evaluating the relationship between
attained reduction in systolic BP and relative risk of each outcome, stratified by drug class. Where a BP-dependent
effect exists (two-tailed p value < 0.05), relative risks, standardised per 10 mmHg difference in BP, will be reported for
each study outcome. Publication bias will be examined using Funnel plots, and calculation of Egger’s statistic.
Discussion: This systematic review will provide a detailed synthesis of evidence regarding the relationship between BP
reduction and clinical outcomes with ACEi and ARBs. Greater understanding of the dependency of the effect of each
class on BP reduction will advance insight into the nature of the ARB-MI paradox and guide the future usage of these
agents.
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Introduction
Elevated systolic blood pressure (BP) is a well-established
risk factor for myocardial infarction (MI), stroke, heart
failure, and death [1–4]. This risk may be ameliorated with
antihypertensive treatment: a reduction in systolic BP of
10 mmHg translates into a 17% reduction in the incidence
of coronary artery disease, a 27% reduction in stroke, a
28% reduction in heart failure, and a 13% reduction in
all-cause mortality [5]. Pharmacological inhibition of the
renin-angiotensin-aldosterone system has been robustly
demonstrated to reduce blood pressure by numerous
randomised clinical trials, meta-analyses and observational
studies [6, 7]. However, controversy persists over the com-
parative safety and efficacy of angiotensin-converting
enzyme inhibitors (ACEis) and angiotensin II receptor
blockers (ARBs), particularly with regard to myocardial
infarction (MI) [8, 9]. Despite robust evidence that ARBs
reduce BP, stroke and heart failure, no study has demon-
strated a significant, protective impact of ARBs for MI,
cardiovascular or all-cause mortality—endpoints reduced
by ACEis in multiple trials [7, 10]. Indeed, in several stud-
ies, a potential ARB-associated increased risk of MI has
been suggested [11, 12]. That ARBs reduce BP—but not
MI—has been described as the ‘ARB-MI paradox’ [13].
Several putative biological hypotheses for this paradox
have been advanced. Firstly, ARBs may have a pharmaco-
logical action that increases the risk of MI, independent
of, and partially masked by their blood pressure-lowering
effects [13]. ARBs induce selective antagonism of the
angiotensin II type I (AT1) receptor, reducing downstream
aldosterone secretion, salt and water retention. However,
AT1 inhibition uncouples the angiotensin II negative feed-
back loop, leading to marked counterregulatory upregula-
tion; angiotensin II levels increase 2- to 3-fold from
baseline [14]. Putatively, this could lead to a greater risk of
MI via increased stimulation of angiotensin II type II
(AT2) receptors, which are overexpressed in atheromatous
plaques, and may promote plaque vulnerability [15]. Other
plausible adverse effects of AT1 blockade include increases
in plasminogen activator inhibitor-1 (PAI-1) and reduc-
tions in bradykinin. Conversely, ACEis suppress angioten-
sin II synthesis and inhibit the breakdown of bradykinin;
yielding synergistic cardioprotective effects.
Some authors have dismissed the validity of the
ARB-MI paradox; attributing the lack of observed bene-
fit to a ‘generation gap’ between trials of ACEis and
ARBs [9]. The primary ARB trials were performed a
decade following the seminal ACEis trials, during which
there was greater availability of evidence-based primary
and secondary prevention strategies, and coronary revas-
cularisation techniques. However, treatment-related re-
ductions in BP would still be expected to translate into
reduced incidence of MI and death, independent of
background therapy and the contemporaneous standard
of care. Although head-to-head trials comparing ACEis
and ARBs represent the only truly objective means by
which to assess the ARB-MI paradox, there exists a pau-
city of such high-quality clinical trial and meta-analysis
data. In the most recent meta-analysis of head-to-head
ACEi-ARB trials, which included 5 trials of 22,542 pa-
tients without heart failure, the risk of MI with ARBs
was not significantly different than with ACEis (RR 1.07,
95% confidence intervals, CI 0.94–1.22) [10]. The risk of
all-cause mortality, in 7 studies, was similar between
ARB and ACEi groups (RR 0.98, 95% CI 0.90–1.07). The
majority of patients included in these analyses (~76%)
originated from the ONTARGET study [16]. Despite a
marked ARB-associated reduction in systolic BP (ex-
pected to translate into a risk reduction of up to 5%),
ONTARGET reported no significant associated benefit
of ARB over ACEi.
Evaluation of the association between treatment-
associated BP reduction and incidence of clinical out-
comes will provide greater insight into the mechanism of
the ARB-MI paradox, and advance understanding of the
comparative safety and efficacy of ACEis and ARBs.
Objectives
We aim to perform a systematic review and meta-analysis,
of all available ACEi and ARB randomised controlled trial
data. Analysis will be performed using summary-level
data. Specifically, we will (i) investigate the extent to which
the reported clinical outcomes in randomised trials of
ACEis and ARBs are attributable to changes in systolic BP,
using meta-regression, and (ii) ascertain if either class of
drug has activity independent of BP reduction. We will
calculate effect sizes, standardised per 10 mmHg differ-
ence in systolic BP, for each study outcome, where a
BP-dependent effect is observed (see below).
Methods
This protocol is in compliance with the relevant extension
of the Prospective Reporting Instructions for Systematic
Review and Meta-Analysis Statement; PRISMA-P (see
Additional file 1) [17]. Final reporting of this study will be
compliant with the main PRISMA statement [18]. This
study is registered on PROSPERO, an international regis-
ter of systematic reviews (CRD42017072988) [19]. This
project was exempt from formal institutional ethical
review. A summary of the key elements of the design of
this study (PICO; population, intervention, comparison
and outcome) is presented in Table 1.
Eligibility criteria
The study inclusion criteria are (i) randomised, placebo
or active comparator-controlled studies, (ii) use of a pro-
spective, randomised, open, blinded end-point (PROBE)
design [20], (iii) trials evaluating at least one drug of the
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ACEi class (benazepril, captopril, cilazapril, delapril,
enalapril, fosinopril, imidapril, lisinopril, moexipril, peri-
ndopril, quinapril, ramipril, spirapril, temocapril, trando-
lapril or zofenopril) or the ARB class (azilsartan,
candesartan, eprosartan, fimasartan, irbesartan, losartan,
olmesartan, telmisartan or valsartan), administered or-
ally, (iv) investigator-choice of specific comparator agent
(within a drug class), (v) any indication for ACEi or ARB
therapy (hypertensive and non-hypertensive partici-
pants), (vi) human, phase II, III or IV studies, reporting
clinical outcomes, (vii) studies reporting at least 500
patient-years of prospective follow-up in each study arm
and (viii) studies of combination drug regimens, in
which one of the regimens includes an ACEi or ARB.
No date restrictions will be applied. No language restric-
tions will be applied; translation will be sought where
necessary. Conference abstracts and other so-called ‘grey
literature’ will only be included if a corresponding full,
peer-reviewed publication is identifiable.
The study exclusion criteria are (i) studies that do not
report relevant clinical endpoints (at least one of MI,
all-cause mortality, stroke, heart failure, revascularisation
or cardiovascular mortality), (ii) studies in which the con-
trol group received no treatment (i.e. neither placebo, nor
active treatment), (iii) studies retracted subsequent to ini-
tial publication and (iv) lack of sufficient data to calculate
between-group differences in systolic BP.
Trials that predominantly recruit participants with
heart failure (HF) at baseline will be included in this
meta-regression study. Previous meta-regression ana-
lyses have also pooled data from both hypertension and
HF studies of renin-angiotensin inhibition [21]. Given
that hypertension is a leading risk factor for the develop-
ment of HF and both frequently co-exist, we feel that
the inclusion of both categories of trial is justified. Trials
enrolling hypertensive patients (including those targeting
non-HF populations) included significant number of
patients with left ventricular impairment, and vice-versa.
For example, of the 5193 patients that had ejection frac-
tion measured in the HOPE study, 421 (8.1%) had an
ejection fraction < 0.40 [22]. Furthermore, trials enrolling
participants with HF generally have a lower between-group
difference in blood pressure (from enrolment to follow-up),
and greater event rate than trials of hypertensive partici-
pants [23]. Therefore, if a bias was introduced by the
inclusion of trials recruiting subjects with heart failure, it
would be towards the null.
All studies of the ACEi and ARB class, vs. placebo or
active comparator, will be included in meta-regression
analysis. Studies that report head-to-head comparison of
ACEi and ARB will be excluded in sensitivity analysis,
once in which the ACEi group is the control class, and
once in which the ARB is the control class.
Information sources
A pre-specified search strategy will be performed, query-
ing the following bibliographic databases, from inception
to the present date: (i) MEDLINE (NCBI PubMed; from
1946), (ii) ISI Web of Science (Clarivate Analytics, NY,
USA; from 1900), (iii) EMBASE (Elsevier, Amsterdam,
NL; from 1947) and (iv) the Cochrane Central Register
of Controlled Trials (The Cochrane Collaboration,
London, UK; from 1966). Unpublished trials will be
identified using ClinicalTrials.gov (from 1997). Literature
that has not undergone formal publication (‘grey litera-
ture’, including conference proceedings, dissertations and
theses) will be identified using The Conference Proceed-
ings Citation Index and the OpenGrey website (via
http://www.opengrey.eu/). This will be used to identify
peer-reviewed publications based on these data. Where
the grey literature source is the only record of the execu-
tion of a study, it will not be included in the synthesis.
The expected impact of the non-publication of such data
will be qualitatively discussed, and (if examples are
present), will be included as a sensitivity analysis. The
reference lists of previous meta-analyses and clinical
trials of the ACEi and ARB class will be retrieved and
scrutinised to identify studies that may otherwise be
overlooked (backward citation searching). Citation lists
of included studies will also be checked (forward citation
searching).
Search strategy
A broad and comprehensive search strategy was devel-
oped following a scoping review of the topic area. The
search strategy will include both free-text (title and
abstract keyword) searching and controlled vocabulary
searching (e.g. the MEDLINE Medical Subject Heading
[MESH] terms). Terms will be grouped by two concepts:
(i) drug identifier terms, including the names of individual
Table 1 A summary of the main study elements in PICO format
Study elements Description
Participants Patients with an indication for inhibition of
the renin-angiotensin aldosterone system,
stratified into those with (i) hypertension
and (ii) heart failure.
Intervention Angiotensin II receptor blockers (ARBs)
and angiotensin-converting enzyme
inhibitors (ACEis)
Control or comparison Placebo, or other classes of antihypertensive
agent
Outcome Standardisation will be performed to estimate
the effect of a 10 mmHg reduction in blood
pressure with each class of drug on the relative
risk of each outcome.
Primary: myocardial infarction and all-cause
mortality
Secondary: cardiovascular mortality, stroke,
heart failure and revascularization
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agents (e.g. perindopril) and relevant drug classes (e.g.
angiotensin-converting enzyme inhibitors) and (ii) clinical
trial identifier terms (e.g. randomised, randomised). The
search strategy was adapted from the Cochrane Highly
Sensitive Search Strategy (sensitivity-maximising version)
[24]. The primary MEDLINE search strategy is presented
in Additional file 2. Searches with equivalent syntax have
been adapted to query the other bibliographic databases
described above. The search strategy will be performed
centrally, querying all data sources on a single date. All
search results will be exported and stored in eXtensible
Markup Language (.xml) format. Duplicate records identi-
fied from multiple sources will be collapsed into a single,
unique entry.
Study records
Selection process
Two independent reviewers will conduct a preliminary
screen of all records identified by bibliographic
searching; assessing each record for relevance accord-
ing to pre-specified eligibility criteria. Studies that
cannot be conclusively excluded by title and abstract
screening will be advanced to full-text screening.
Full-text articles will be retrieved in Portable Docu-
ment Format (.pdf ), and comprehensively reviewed
using a 2-stage process. The first stage will assess the
study with regard to design; the second stage will as-
sess the study with regard to reporting of blood pres-
sure differences and outcomes. Discrepancies between
the two reviewers at any stage will be resolved
through discussion, and if required, final arbitration
will be performed by the senior authors (MHS and
ASH). The flow of studies through the selection
process, together with reasons for exclusion at the
full-text stage, will be reported using a modified
PRISMA diagram, as in Fig. 1.
Data management
Retrieval and storage of study records, abstracts and
full-text articles will be performed using EndNote X8
(Thomson Reuters, NY, USA). The primary database will
be stored on a server-based platform to enable real-time
synchronisation of data between investigators.
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart depicting the proposed study selection
process.*Other sources are described in full in the ‘Information sources’ section
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Data extraction
Extraction of relevant data from included studies will be
independently performed by JAB and MT. The concord-
ance of each data point following extraction by both au-
thors will be evaluated. Discrepancy will be resolved by
discussion; final arbitration will be performed by MHS
and ASH. A custom data extraction form will be piloted
and optimised using a subset of five randomly selected
studies satisfying the eligibility criteria. For those studies
that satisfy the first stage of the eligibility screening
process, but fail to report elements of necessary data
(e.g. between-group differences in blood pressure, spe-
cific clinical endpoints) in the main study publication or
supplementary appendices, the following steps will be
taken: (i) searching for other peer-reviewed publications
based on the primary study data, (ii) checking whether
data are available in previous meta-analyses of this topic,
(iii) searching for third-party sources of data, including
US Food and Drug Administration (FDA) dockets, and,
(iv) requesting data from the study author and/or spon-
sor. When data are not available from the primary study
manuscript, a record of the data source will be made. If
the minimum analytic dataset cannot be ascertained,
such studies will be excluded. The expected effect of
such exclusion (with regard to bias of the final ana-
lysis and results) will be summarised qualitatively in
the final report.
When multiple publications arise from one study, rele-
vant data will be extracted into a single form. Studies
evaluating more than two groups, (e.g. ACEi vs. calcium
channel blocker vs. placebo), are expected to occur in-
frequently in this context. For such studies, the group
‘shared’ in multiple comparisons (ACEi, in this example)
and corresponding number of events will be equally di-
vided, as outlined in the Cochrane Handbook for Sys-
tematic Reviews of Interventions [25]. This partially
overcomes the unit-of-analysis (double-counting) error,
although it is recognised that the resulting comparisons
remain correlated. Sensitivity analyses, excluding such
studies, will be performed to evaluate the extent of any
bias that may be introduced.
Data items
All data items to be extracted are summarised in Table 2.
Where conflicting, overlapping or duplicate study data are
presented in multiple reports, only the most comprehen-
sive or recent will be used, and the remainder discarded.
Based on initial pilot analysis, the mean between-group
difference in systolic BP during follow-up (or data re-
quired to robustly calculate between-group difference in
systolic BP) is consistently well-reported in the relevant
trials. Of 20 studies selected randomly that fulfil the pro-
posed inclusion criteria, the mean between-group differ-
ence in BP was reported, or calculable, in 18 (90%). When
not reported directly in the study manuscript, calculation
will be performed. A schema for this measure is presented
in Fig. 2. Reported differences in systolic BP will be ex-
tracted in preference to calculated differences; differences
in systolic BP at the final study visit (from baseline) will be
extracted in preference to mean or median differences
during follow-up. However, where only average decreases
in systolic BP are reported, these would be expected to re-
sult in bias towards the null, and therefore will be in-
cluded. In the event that summary statistics other than
mean and standard deviation are reported (e.g. median
and interquartile range, confidence intervals), the recom-
mended approach of Hozo et al. will be employed [26].
Pilot analysis has suggested that the expected range of
between-group differences in systolic blood pressure lies
between 5 and − 20 mmHg (maxima and minima, respect-
ively), with an expected standard deviation of approxi-
mately 5 mmHg. This degree of variability approximates
well with that observed in a previous meta-analysis [21].
Outcomes
The primary outcomes will be MI (non-fatal and fatal, in-
cluding sudden death) and all-cause mortality (death from
any cause). These outcomes were chosen as the focus of
current inquiry as they represent the source of persisting
controversy, and are measured most consistently across
studies. Secondary outcomes were cardiovascular mortality
(defined as per study; often a composite of fatal myocardial
infarction, stroke, peripheral vascular disease and sudden
death), stroke (non-fatal and fatal), heart failure requiring
hospitalisation, and unplanned revascularisation. The num-
ber of events occurring in the total at-risk population
(using intention-to-treat analysis, if reported) will be ex-
tracted. This will be used to calculate a risk ratio for each
study, which will be reported in addition to the raw data.
When these endpoints are not reported verbatim in
studies (e.g. only fatal MI is reported), this will be in-
cluded, with appropriate acknowledgement in the final
report. The hierarchy for reporting non-specific out-
comes is presented in Table 3.
Where few outcomes are observed, resulting in a
divide-by-zero error and unspecified risk ratio, one out-
come will be added to each cell, in order to permit in-
clusion of the study. For example, in a hypothetical trial
in which there were three deaths in the control arm and
none in the active comparator arm, it would be impos-
sible to calculate a risk ratio. The addition of one event
to each cell of the contingency table would permit
estimation of the relevant ratio measures.
Risk of bias in individual studies
The risk of bias will be ascertained by two reviewers in
parallel, using The Cochrane Risk of Bias Tool [27].
Assessment will be performed at the study level, and will
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Table 2 Dictionary of items to be extracted from included studies, with description and rationale
Data item Description and rationale
Study characteristics
Study ID Unique identifier for each study retrieved.
Trial acronym/first author Either the trial acronym (if applicable, e.g. HOPE, VALUE) or first
author of the primary study report if not (e.g. Smith AB et al.).
Year Year of primary study publication.
Study design Placebo-controlled, active comparator-controlled or PROBE design.
Duration of follow-up Time period (in months) over which participants underwent follow-up
Age Mean age of all patients included in analysis.
Sex Number (%) of male study participants.
Hypertension Number (%) of study participants with hypertension.
Heart failure Number (%) of study participants with heart failure.
Diabetes Number (%) of study participants with diabetes.
Ischaemic heart disease Number (%) of study participants with ischaemic heart disease.
Loss to follow-up Number (%) of study participants lost to follow-up
Revascularisation Number (%) of study participants that underwent invasive coronary revascularisation
Concomitant drug therapy Number (%) of study participants receiving other cardiovascular agents
(β-blockers, calcium channel blockers, etc.)
Exposures and outcomes for each group
Group class Class of agent in the intervention and comparator arms (i.e. ACEi or ARB and
placebo or active comparator).
Group agent Identity of agent given to participants randomised to the intervention
and comparator arms
n in group Number in intervention and comparator arms (included in final analysis)
Baseline SBP Baseline systolic blood pressure (mmHg) in each group. If multiple are provided
(e.g. sitting, ambulatory, supine, etc.) sitting/clinic measurement will be used.
Follow-up SBP Systolic blood pressure measured during follow-up in each group (mmHg). Any
SBP measured at ‘steady-state’ during follow-up, or SBP averaged across visits
may be included. If serial measurements are reported, the last measurement
will be extracted. SBP after the first-dose of the medication will not be included.
Within-group difference in SBP The within-group change in SBP from baseline to follow-up either directly
reported or calculated as per Fig. 2. Directly reported differences will supersede
calculated values.
Between-group difference in SBP The between-group difference in SBP change, either directly reported or calculated
as per Fig. 2. Directly-reported differences will supersede calculated values.
Baseline DBP Baseline diastolic blood pressure (mm Hg) in each group. If multiple are provided
(e.g. sitting, ambulatory, supine, etc.) sitting/clinic measurement will be used.
Follow-up DBP Diastolic blood pressure measured during follow-up in each group (mm Hg). Any
DBP measured at ‘steady-state’ during follow-up, or SBP averaged across visits
may be included. If serial measurements are reported, the last measurement
will be extracted. DBP after the first-dose of the medication will not be included.
Within-group difference in DBP The within-group change in DBP from baseline to follow-up either directly
reported or calculated as per Fig. 2. Directly-reported differences will
supersede calculated values.
Between-group difference in DBP The between-group difference in DBP change either directly reported
or calculated as per Fig. 2. Directly reported differences will supersede
calculated values.
All-cause mortality The total number of deaths, of any cause, that occur in each group
during follow-up. If the denominator is different to ‘n in group’, this
must be specified.
Cardiovascular mortality The number of cardiovascular deaths that occur in each group
during follow-up. If the denominator is different to ‘n in group’,
this must be specified.
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focus on selection, performance, detection, attrition and
reporting biases. The risk of bias for each included study
will be taken into consideration during data synthesis.
Sensitivity analysis, excluding those studies at greatest
risk of bias, will be performed. In addition, the Grades
of Recommendation, Assessment, Development, and
Evaluation (GRADE) system will be used to summarise
the quality of evidence, for each outcome [28].
Data synthesis
Studies will be included in qualitative and quantitative
synthesis if they fulfil all eligibility criteria. Notable re-
cords discarded during the screening procedure will be
discussed, particularly if these required arbitration, or
have been specifically included in or excluded from pre-
vious meta-analyses. Study characteristics will be sum-
marised using means and standard deviations (or
medians and interquartile ranges) for continuous vari-
ables, and numbers and percentages for categorical
variables. A narrative report of study characteristics will
also be provided.
Between-study heterogeneity will be estimated char-
acterised using the I2 statistic and quantified using
Cochran’s Q statistic. Sources of heterogeneity, derived
from the clinical characteristics of patients enrolled to
each study (Table 2) will be examined. In the absence
of significant between-study heterogeneity, inverse
variance-weighted fixed-effects meta-analysis will be
performed. Random-effects meta-analysis, using the
methodology of DerSimonian and Laird, will be per-
formed as a sensitivity analysis [29]. The pooled effect
estimate (relative risk, RR) will be reported with corre-
sponding 95% confidence intervals and p values. All p
values will be calculated using two-tailed tests, with
type I error of 0.05. Additionally, standardisation will
be performed to estimate the pooled effect of a
10 mmHg reduction in blood pressure with each class
of drug on the relative risk of each outcome, with cor-
responding 95% confidence intervals. This will be
Table 2 Dictionary of items to be extracted from included studies, with description and rationale (Continued)
Data item Description and rationale
Definition of cardiovascular mortality Study definition of cardiovascular mortality, as per Table 2, below.
Myocardial infarction The number of myocardial infarctions that occur in each group during
follow-up. If the denominator is different to ‘n in group’, this must be
specified.
Definition of myocardial infarction Study definition of cardiovascular mortality, as per Table 2, below.
Stroke The number of strokes that occur in each group during follow-up.
If the denominator is different to ‘n in group’, this must be specified.
Definition of stroke Study definition of stroke, as per Table 2, below.
Only data items for direct extraction are presented above. Calculation of group specific event rates, etc. will be performed during the analytic phase of the study.
PROBE prospective randomised open-blinded end-point study design
Fig. 2 Schema illustrating calculation of mean between-group difference in blood pressure. Hypothetical data are presented. In this example, the
mean between-group difference in blood pressure would be (195–185) − (195–170) = 10–25 = − 15 mmHg. That is, the intervention drug reduced
blood pressure, on average, by 15 mmHg more than the control drug (placebo or active comparator)
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performed using the methodology of Tierney et al.
using the formula below [30, 31].
RRstandardised ¼ e
10
P
ΔSBPi ∙Wi ∙ log RRið ÞP
ΔSBPi
2 ∙Wi
Where ΔSBPi is the between-group difference in sys-
tolic BP, log (RRi) is the natural log-transformed relative
risk for each outcome and Wi is the inverse variance, for
each trial, i. Meta-regression will be performed to iden-
tify the impact of blood pressure reduction as a moder-
ator of clinical outcome, and evaluate the assumption
that reductions in RR will be proportional to the
achieved reduction in BP. Meta-regression plots, with
95% confidence intervals, will be plotted by drug class
and outcome. Relative risk will be plotted against
between-group reduction in systolic BP. The x-axis
intercept will be examined to assess the blood
pressure-dependency of the effect of each agent (i.e. a
reduction in clinical endpoints at a between-group
difference in BP of 0 mmHg implies pharmacological ac-
tivity independent of BP reduction). Subgroup analysis
will be performed to address the presence of interaction
with (i) overall duration of study follow-up, (ii) percent-
age usage of other agents (β blockers and calcium
channel blockers), (iii) percentage of study participants
revascularised, (iv) year of study publication and (v) enrol-
ment period of patients; each categorised appropriately. p
values for interaction will be presented for each case. The
presence of meta-bias (specifically, publication bias) will be
examined by visual inspection of Funnel plots and calcula-
tion of Egger’s statistic, for both ACEi and ARB trials. All
analyses will be performed using Stata (version 14.0; Stata-
Corp, College Station, TX, USA) and R (version 3.4.1; The
R Foundation for Statistical Computing, Vienna, Austria).
Narrative evaluation of the risk of bias in individual studies
will be undertaken to suggest the overall strength of the
body of evidence.
Sensitivity analyses
All studies of the ACEi and ARB class, vs. placebo or active
comparator, will be included in the primary meta-
regression analysis. Multiple sensitivity analyses will be per-
formed to evaluate restriction of analysis to exclude studies
with (a) open-label (e.g. PROBE) design, (b) head-to-head
comparison of ACEi and ARB only, (c) high-risk of bias, (d)
greater than two randomisation arms and (e) principal
recruitment of participants with HF. Both fixed effects (in-
verse variance-weighted) and random effects (DerSimonian
and Laird-weighted) will be performed.
Table 3 The hierarchy of outcomes to be extracted and included in final data synthesis
Outcome Status Rank Explanation
All-cause mortality Primary 1 Total number of deaths in each study group due to any attributed cause.
Myocardial infarction Primary 1 Non-fatal or fatal myocardial infarction, or sudden cardiac death
2 Non-fatal or fatal myocardial infarction
3 Fatal myocardial infarction, or sudden cardiac death
4 Non-fatal myocardial infarction only
5 Fatal myocardial infarction only
6 Any other definition of a myocardial infarction-related endpoint
Cardiovascular mortality Secondary 1 Fatal myocardial infarction, stroke, other cardiovascular disease or sudden death
2 Fatal myocardial infarction, stroke or other cardiovascular disease
3 Fatal myocardial infarction, stroke or sudden death
4 Fatal myocardial infarction or stroke
5 Any other definition of cardiovascular mortality
Stroke Secondary 1 Non-fatal or fatal stroke, not including transient ischaemic attack
2 Fatal stroke
3 Non-fatal stroke
4 Non-fatal stroke or transient ischaemic attack
5 Non-fatal or fatal stroke or transient ischaemic attack
6 Any other definition of a stroke-related endpoint
Revascularisation Secondary 1 Any need for unplanned revascularisation
Heart failure Secondary 1 Management of heart failure, requiring medical attention, hospital attendance or admission
Rank 1 is the preferred outcome definition to be extracted and included in data synthesis. In the event of a study not reporting the first-ranked outcome, and this
data not being available from contacting authors and sponsors, the next lowest ranked endpoint reported (or calculable without double-counting) in each study
will be included in final data synthesis
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Discussion
The existence and mechanism of an ARB-MI paradox is
controversial. We envisage that this systematic review
will provide a detailed, state-of-the-art and unbiased syn-
thesis of the evidence regarding the relationship between
clinical outcomes and BP reduction as a result of treat-
ment with ACE inhibitors and ARBs. To date, several
methodologically similar meta-regression analyses have
been performed. One such analysis included only those
trials participating in the Blood Pressure Lowering
Treatment Trialists’ Collaboration; lacking a systemic
methodological rigour [21]. A search strategy, study in-
clusion and exclusion criteria were not defined on an a
priori basis. Furthermore, this study was likely under-
powered, in part due to the era in which it was per-
formed (pre-2005). As such, this study is unlikely to
represent an unbiased representation of all available clinical
evidence. Emergence of further relevant studies in the
intervening period may enable sufficient power to form
additionally robust conclusions. Further analyses, not re-
stricted to the ACEi and ARB class, report a consistent re-
lationship between reductions in BP and cardiovascular
risk reduction [5, 32]. However, between-class ACE-ARB
comparisons were not the major focus of such studies [33].
Previous meta-regression analyses (such as that by
Messerli et al. [10]) estimated whether ACEi or ARB
treatment effects (on a relative risk scale) were associ-
ated with the underlying baseline risk, as measured by
the event rate observed in the control group. This is a
flawed approach, which produces misleading results [34,
35]. Specifically, the independence assumption of regres-
sion is invalidated; the control event rate is included in
the denominator of the relative risk estimate. In the
absence of any true association, such analyses will always
determine that an observed benefit will be more pro-
nounced in trials with high control group event rates,
than trials with low control group event rates; a
self-fulfilling prophecy [36].
Greater characterisation of the relationship between
drug-mediated BP reductions and clinical outcomes may
better guide utilisation of ACE inhibitors and ARBs, and
may highlight the need for further analysis, using indi-
vidual participant-level randomised trial data.
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